Becton, Dickinson and Company
BDXHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 18, 2026
Scan Results
Daily timeframeBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science. Valued at $43.58B, BDX is a large-cap name in its sector. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Market Cap
$43.58B
Beta
0.27
P/E (TTM)
27.95
P/E (Fwd)
11.79
EPS (TTM)
$5.66
EPS (Fwd)
$13.42
ROE
6.7%
ROA
4.4%
Cash
$816.0M
Total Debt
$17.28B
Free CF
$4.53B
52W Change
12.5%
Annual Financials
Cash vs Debt
On the balance sheet, BDX has $816.0M in cash with $17.28B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $4.53B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 6.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.4% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $18.87B to $21.84B.
The relatively low beta of 0.27 suggests BDX is a less volatile holding compared to the broader index. Becton, Dickinson and Company carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BDX.